Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.
|Articles|February 8, 2004
How do you measure the quality of life impact by melanoma?
Washington D.C. Sandra Bendeck, M.D. presented at the AADyesterday about ways that physicians can measure the quality of life impactby melanoma. Since the incidence of melanoma is increasing by four percentevery year, it is increasingly important to determine the impact of thisillness on patients, both physically and psychologically.
Advertisement
Advertisement
Related to this article
Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
Explore trending plant oils in skincare and haircare, plus 2026’s hottest actives like ectoin and hypochlorous acid—balancing glow, barrier repair, and irritation risks.
Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases.
Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
3
Menopause and the Skin: Recognizing Changes Beyond Aging
4
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
5